O
Outlook Therapeutics, Inc. (OTLK)
NCM – Real vaqt narxi. Valyuta: USD
1.71
+0.10 (6.21%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.70
-0.01 (-0.82%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.71
+0.10 (6.21%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.70
-0.01 (-0.82%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Outlook Therapeutics, Inc. klinik bosqichdagi biofarmatsevtika kompaniyasi bo'lib, oftalmik ko'rsatmalar uchun monoklonal antitelalarni ishlab chiqish va tijoratlashtirishga qaratilgan. Uning asosiy mahsulot nomzodi ONS-5010 bo'lib, bu bevacizumab mahsulotining oftalmik formulasi bo'lib, u nam yoshga bog'liq makula degeneratsiyasi va boshqa retina kasalliklarini davolash uchun III fazali klinik sinovda. Outlook Therapeutics, Inc. Cencora bilan hamkorlik shartnomalariga ega. Outlook Therapeutics, Inc. ilgari Oncobiologics, Inc. nomi bilan tanilgan va 2018-yil noyabr oyida Outlook Therapeutics, Inc. nomini o'zgartirgan. Outlook Therapeutics, Inc. 2010-yilda tashkil etilgan va Iselin, Nyu-Jersi shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs |
| Mr. Jedd Comiskey | Senior VP - Head of Europe |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A |
| Mr. Lawrence A. Kenyon CPA | EVP, CFO, Treasurer, Secretary & Director |
| Mr. Robert Charles Jahr | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 8-K | tm2619105d1_8k.htm |
| 2026-06-16 | 8-K | tm2618010d1_8k.htm |
| 2026-06-01 | DEFA14A | ny20071594x3_defa14a.htm |
| 2026-06-01 | DEF 14A | ny20071594x2_def14a.htm |
| 2026-06-01 | 8-K | tm2616461d1_8k.htm |
| 2026-05-29 | 8-K | tm2615979d1_8k.htm |
| 2026-05-28 | 8-K | tm2615925d1_8k.htm |
| 2026-05-26 | 8-K | tm2615583d1_8k.htm |
| 2026-05-22 | PRE 14A | ny20071594x1_pre14a.htm |
| 2026-05-18 | 8-K | tm2614868d1_8k.htm |